Pa., Oct. 20, 2022 /PRNewswire/ -- (NYSE:
ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage
drug platform company addressing neurodegenerative diseases,
announced today that it will present at the ThinkEquity 2022
Investor Conference on Wednesday, October 26,
2022, in New York City.
Presentation time: 9:00 am ET to 9:30 am
Date: October 26,
Location: The Mandarin Oriental Hotel
in New York
Investors interested in arranging a one-on-one meeting at the
conference should contact their ThinkEquity representative.
Buntanetap (previously known as ANVS401 or Posiphen) is an oral
translational inhibitor of neurotoxic aggregating proteins
(TINAPs), which mode of action leads to a lower level of neurotoxic
proteins and consequently less toxicity in the brain. In a Phase 2a
clinical trial in AD and PD patients, buntanetap was shown to be
well-tolerated and safe, and its pharmacokinetics were found to be
in line with levels measured earlier in humans, meeting both the
primary and secondary endpoints. Additionally, exploratory
endpoints were also met, as treatment with buntanetap resulted in
statistically significant improvement in motor function in PD
patients and cognition in AD patients. Presently buntanetap is
being studied in a phase 3 early PD study and will enter a phase
2/3 study in AD patients later in the year.
About Annovis Bio, Inc.
Headquartered in Berwyn,
Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug
platform company developing transformative therapies that treat
neurodegenerative disorders such as Alzheimer's disease (AD),
Parkinson's disease (PD) and other chronic and acute
neurodegenerative diseases. The Company believes that it is the
only company developing a drug that inhibits more than one
neurotoxic protein, improves the information highway of the nerve
cell, known as axonal transport, reduces inflammation and protects
nerve cells from dying in chronic and acute neurodegeneration.
Annovis conducted two Phase 2 studies: one in AD patients and one
in both AD and PD patients. In the AD/PD study, buntanetap showed
improvements in cognition and memory in AD as well as body and
brain function in PD patients.
For more information on Annovis Bio, please visit the Company's
website www.annovisbio.com and follow us on LinkedIn and
Statements in this press release contain "forward-looking
statements" that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as "anticipate,"
"expect," "believe," "will," "may," "should," "estimate,"
"project," "outlook," "forecast" or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness, and anticipated results of buntanetap clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.'s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2021, filed
with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Annovis Bio, Inc. undertakes no duty to update such information
except as required under applicable law.
Media and Investor Contact:
Russo Partners, LLC
View original content to download
SOURCE Annovis Bio